NCT02418143
Withdrawn
Not Applicable
A Post Market Observational Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
ConditionsCoronary Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Disease
- Sponsor
- Aziyo Biologics, Inc.
- Primary Endpoint
- Device Related Adverse Events
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
Actively gather additional information on the use of CorMatrix CanGaroo ECM Envelope in a post market observational study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject who has received the CorMatrix CanGaroo ECM Envelope for an implantable electronic device following battery change out or upgrade.
- •Signed Informed Consent
Exclusion Criteria
- •Known sensitivities to porcine material.
Outcomes
Primary Outcomes
Device Related Adverse Events
Time Frame: 1 day post-operative follow up visit
Similar Trials
Completed
Not Applicable
Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)Coronary DiseaseNCT02073331Aziyo Biologics, Inc.1,420
Completed
Not Applicable
A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) EnvelopeCardiovascular DiseaseNCT02530970Aziyo Biologics, Inc.1,025
Completed
Not Applicable
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic DrugsRheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisNCT01083693Abbott162
Terminated
Not Applicable
A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckUnresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckLA SCCHNNCT01303237Merck KGaA, Darmstadt, Germany88
Terminated
Phase 4
Single Arm Post-marketing Study of SC20 ColonoscopeGentle ColonoscopyNCT02279836Invendo Medical GmbH2